Sec. 744. BRIEFING ON DOMESTIC PRODUCTION OF CRITICAL ACTIVE PHARMACEUTICAL INGREDIENTS FOR NATIONAL SECURITY PURPOSES

301 words·~1 min read·/statute-compilations/comps-16861/sec-744

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

## SEC. 744 BRIEFING ON DOMESTIC PRODUCTION OF CRITICAL ACTIVE PHARMACEUTICAL INGREDIENTS FOR NATIONAL SECURITY PURPOSES Not later than April 1, 2022, the Secretary of Defense shall provide to the Committees on Armed Services of the House of Representatives and the Senate a briefing on the development of a capability for the domestic production of critical active pharmaceutical ingredients and drug products in finished dosage form for national security purposes. Such briefing shall include a description of the following: ####

(1)The anticipated cost over the period covered by the most recent future-years defense program submitted under section 221 of title 10, United States Code (as of the date of the briefing), to develop such a domestic production capability for critical active pharmaceutical ingredients. ####

(2)The cost of producing critical active pharmaceutical ingredients through such a domestic production capability, as compared with the cost of standard manufacturing processes used by the pharmaceutical industry. ####

(3)The average time to produce critical active pharmaceutical ingredients through such a domestic production capability, as compared with the average time to produce such ingredients through standard manufacturing processes used by the pharmaceutical industry. ####

(4)Any intersections between the development of such a domestic production capability, the military health system, and defense-related medical research or operational medical requirements. ####

(5)Lessons learned from the progress made in developing such a domestic production capability as of the date of the briefing, including from any contracts entered into by the Secretary with respect to such a domestic production capability. ####

(6)Any critical active pharmaceutical ingredients that are under consideration by the Secretary for future domestic production as of the date of the briefing. ####

(7)The plan of the Secretary regarding the future use of such a domestic production capability for critical active pharmaceutical ingredients.